Autism spectrum disorders are a group of neurodevelopmental disorders with a complex and heterogeneous etiology. Studies have shown that genetic factors play an important role in the aetiology of these diseases. Recently, de novo mutations, frameshifts and deletions have been described in the SHANK3 gene, also known as ProSAP2 gene, which encodes a synaptic scaffolding protein. All the participants of this study had normal karyotypes and underwent screening for Fragile-X syndrome. Subsequently, they were analyzed by direct sequencing of different points of exons 8 and 22 of the SHANK3 gene. None of the study participants presented with changes in these regions. These findings may be due to the fact that mutations, deletions and duplications of the SHANK3 gene are rare.
Introduction
Autism Spectrum Disorders (ASDs) are a clinically complex group of childhood disorders that have firm evidence of an underlying genetic etiology. 1 The group of ASDs includes autism, as well as Pervasive Developmental Disorder not otherwise specified (PDD-NOS) and Asperger's syndrome. 2 The diagnosis of ASDs is based on impairments in reciprocal social interaction and communication, and restricted and stereotyped patterns of interests and activities with abnormal development apparent within the first 3 years of life. 3 The prevalence of ASDs is estimated at 1 per 150 children. 4 Cases are isolated or associated and a recognized cause is identified in ~10% of individuals, most commonly fragile-X syndrome, tuberous sclerosis and cytogenetically detectable chromosome abnormalities. 5, 6, 7 Standard karyotype analyses show chromosomal rearrangements in 3%-6% of cases, the most common being deletions and duplications on chromosomes 2q, 7q, 15q and 22q. 8, 9 The SHANK3 gene, mapped on chromosome 22q13.3, has been extensively studied in this population. This gene encodes the postsynaptic density protein (PSD) specialized at excitatory synapses, where it may function as a master scaffolder forming large sheets that may well represent the platform for the construction of the PSD complex, where it binds directly to neuroligins. 10, 11 The PSD is usually located at the tip of dendritic protrusions of about 1-2 µm in length, termed dendritic spines, and separated from the presynaptic transmitter-containing terminal by the synaptic cleft. Thus shank proteins are not considered to provide a direct scaffolding function for transmitter receptors, but rather work indirectly by connecting different types of scaffold/receptor complexes, leading to the concept of a "master" or "higher order" scaffold. This view is strongly supported by different protein interactions in which Shank proteins are involved. 12 In addition to their function of assembling the PSD during synaptogenesis, the SHANK3 protein may play a role in synaptic plasticity and in the regulation of dendritic spine morphology. The lack of one functional copy of the gene would thus lead to severe neurological deficits because individual neurons cannot provide enough Shank proteins for synapse development and maintenance. In addition, it makes sense that the amount of Shank protein in dendrites is tightly controlled, most likely by local synthesis derived from dendritically transported mRNAs, and activity-dependent degradation through the ubiquitin proteasome system.
12
This current pilot study evaluated exons 8 and 22 of the SHANK3 gene by direct sequencing.
Subjects and Methods
This study was approved by the Research Ethics Committee (CEP) of the Medicine School in São José do Rio Preto and CONEP (process 25000.015469/2007-59). After obtaining written informed consent from parents, a total of 30 (22 male and 8 female) unrelated individuals with ASDs were studied. These individuals, of mixed ethnicity and representative of the Brazilian population, were aged from 5 to 30 years old (mean = 14.16 and standard deviation = 6.30 years). Fifteen (50%) were diagnosed as autistic, 11 (36.67%) with PDD-NOS and 4 (13.33%) with Asperger's syndrome. The patients were from two specialized autism schools and all individuals were conclusively diagnosed by psychiatrists using different methods. Additionally, all were evaluated by an interdisciplinary team composed of a psychiatrist, neurologist, geneticist, psychologist, speech therapist and nurse before participating in this study. Besides the clinical evaluation, the diagnosis of ASD was made if the patient met the DSM-IV criteria. Patients were submitted to clinical and karyotypic examinations and molecular investigations of the FMR1 gene. Only those individuals with normal results for these tests were included in the study. We also excluded patients with evidence of any other psychiatric or neurological conditions and those with other genetic syndromes. Genomic DNA was isolated from the leukocytes of peripheral blood 15 and the primer sequences were designed using the Primer3 program. For all patients, the entire exon 8 and parts of the coding region of exon 22 of the SHANK3 gene were screened. and reverse primer 5´-GGGAAGAACCAAGGTTCAGA -3´). Amplification was performed in a reaction volume of 25µL containing 1x PCR Buffer, 50mM of MgCl 2, 1.25mM dNTPs (GE Healthcare), 50ng genomic DNA, 10µM of each primer, and 5U Taq DNA polymerase (Invitrogen). The PCR reaction was carried out in a GeneAmp ® PCR System 9700 (Applied Biosystems, CA) with 4 min of denaturation at 94ºC, followed by 35 cycles of 94ºC for 45s, 45s at an annealing temperature of 62ºC, and for exon 8, an extension for 1 min at 72ºC, with 5 min denaturation at 95ºC, followed by 30 cycles of 95ºC for 30s, 30s at the annealing temperature at 57ºC, and for each primers of exon 22, extension for 1 min at 72ºC. PCR products were purified with ethanol. 16 Sequencing reactions were carried out with the Applied Biosystems Dye-Terminator v3.1 Kit (Applied Biosystems, USA) and analyzed on a 3730 DNA analyzer (Applied Biosystems, CA). Analysis of sequences was performed using the DS Gene 2.0 program (Accelrys, USA) and a comparison with existing sequences was made using GenBank (www.ncbi.nlm.nih.gov/nuccore/24137474). To date 30 individuals have been investigated. Karyotyping was performed when possible on probands resulting in 27 individuals and 9 subjects for molecular genetic testing of the Fragile-X syndrome with one affected individual in each family. Direct sequencing of exon 8 and two exon 22 regions of the SHANK3 gene was performed for all subjects.
Results
All subjects had wild sequences according to Genbank. Thus, all participants had normal sequences from 8700 to 8870, the position of exon 8 in the SHANK3 gene. Furthermore, they were normal considering the regions from 46748 to 46934 and from 47435 to 47617 positions of DNA of exon 22 of the SHANK3 gene when analyzed by direct sequencing.
Discussion
SHANK3 is located on chromosome 22q13.3, spans approximately 57kb and contains 23 exons. Seven of the exons are alternatively spliced, which may influence the spectrum of SHANK-interacting proteins. SHANK3 expression in the brain seems to be confined to the cortex, hippocampus and cerebellum. 17 Owing to its emerging role in neuropsychiatric disorders, SHANK3 was first implicated in the field of neuropsychiatric disorders when a patient with 22q13.3 deletion syndrome was found to have a de novo reciprocal translocation that disrupted the gene. Subsequent studies have identified de novo deletions and mutations of SHANK3 in individuals with autism, thus corroborating with previous reports about the role of the gene within the autistic phenotype.
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Exon 8 of the SHANK3 gene has 78 pb and exon 21 has 2254 pb. A de novo mutation has been described in exon 8, characterized by the exchange of A962G mRNA, which resulted in a heterozygous Q321R substitution. 2 In this study the entire exon 8 was screened in all participants but no changes were identified. A frameshift mutation (E409X) and a 15-nt deletion have also been found in exon 21.
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We initially chose to study this site (exon 21) as it had previously been reported as disrupted 2, 8 , but the sequences of primers described by the authors correspond to exon 22 of the human SHANK3 gene according to GenBank data. In personal correspondence with Christian R. Marshall, one of authors, it was noted that the sequence described was correct, but that it corresponded to exon 22 instead of 21. Thus, we chose to study parts of exon 22 and all the subjects were normal. A correlation between mutations or small cytogenetic rearrangements affecting different exons of SHANK3 and ASD is possible. 2, 14, 19 Based on diagnostic tests, karyotyping and fragile-X testing must be requested for all patients with ASD. In the presence of dysmorphic features and evident neurological symptoms, it is reasonable to suspect the chromosomal rearrangements exist even if the karyotype appears normal. Depending upon availability and cost, BAC or CGH analysis is strongly advised in these cases. As these technologies will become progressively more available, it will be important not to restrict them to patients with dysmorphia, as microdeletions and microduplications are also common among patients with idiopathic, non-dysmorphic ASD. 14 
